Which has preferable earnings and valuation, STTK or CDNA?

CareDx has higher revenue and earnings than Shattuck Labs. Shattuck Labs is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Shattuck Labs $1M 599.17 -$48.81M -$0.51 N/A CareDx $379.80M 7.17 -$21.35M $2.07 25.43

Is STTK or CDNA more profitable?

CareDx has a net margin of 24.23% compared to Shattuck Labs' net margin of 0.00%. CareDx's return on equity of 2.87% beat Shattuck Labs' return on equity. Company Net Margins Return on Equity Return on Assets Shattuck Labs N/A -43.57% -40.90% CareDx 24.23% 2.87% 2.17%

Does the media prefer STTK or CDNA?

In the previous week, CareDx had 2 more articles in the media than Shattuck Labs. MarketBeat recorded 5 mentions for CareDx and 3 mentions for Shattuck Labs. Shattuck Labs' average media sentiment score of 1.69 beat CareDx's score of 1.05 indicating that Shattuck Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Shattuck Labs 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive CareDx 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor STTK or NKTR?

In the previous week, Nektar Therapeutics had 2 more articles in the media than Shattuck Labs. MarketBeat recorded 5 mentions for Nektar Therapeutics and 3 mentions for Shattuck Labs. Shattuck Labs' average media sentiment score of 1.69 beat Nektar Therapeutics' score of 0.84 indicating that Shattuck Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Shattuck Labs 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Nektar Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is VERA or STTK more profitable?

Shattuck Labs' return on equity of -43.57% beat Vera Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Vera Therapeutics N/A -84.13% -66.79% Shattuck Labs N/A -43.57% -40.90%

Does the media favor VERA or STTK?

In the previous week, Vera Therapeutics had 15 more articles in the media than Shattuck Labs. MarketBeat recorded 18 mentions for Vera Therapeutics and 3 mentions for Shattuck Labs. Shattuck Labs' average media sentiment score of 1.69 beat Vera Therapeutics' score of 1.23 indicating that Shattuck Labs is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vera Therapeutics 9 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Shattuck Labs 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is PHVS or STTK more profitable?

Shattuck Labs' return on equity of -43.57% beat Pharvaris' return on equity. Company Net Margins Return on Equity Return on Assets Pharvaris N/A -61.40% -56.00% Shattuck Labs N/A -43.57% -40.90%

Does the media refer more to PHVS or STTK?

In the previous week, Pharvaris had 34 more articles in the media than Shattuck Labs. MarketBeat recorded 37 mentions for Pharvaris and 3 mentions for Shattuck Labs. Shattuck Labs' average media sentiment score of 1.69 beat Pharvaris' score of 0.52 indicating that Shattuck Labs is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharvaris 13 Very Positive mention(s) 5 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Shattuck Labs 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is STTK or PGEN more profitable?

Shattuck Labs has a net margin of 0.00% compared to Precigen's net margin of -183.98%. Precigen's return on equity of 423.75% beat Shattuck Labs' return on equity. Company Net Margins Return on Equity Return on Assets Shattuck Labs N/A -43.57% -40.90% Precigen -183.98% 423.75% 84.39%

Does the media favor STTK or PGEN?

In the previous week, Shattuck Labs had 1 more articles in the media than Precigen. MarketBeat recorded 3 mentions for Shattuck Labs and 2 mentions for Precigen. Shattuck Labs' average media sentiment score of 1.69 beat Precigen's score of 1.40 indicating that Shattuck Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Shattuck Labs 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Precigen 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Shattuck Labs (STTK) Competitors

$5.97 -0.23 (-3.71%)

Closing price 04:00 PM Eastern

Extended Trading

$5.97 0.00 (0.00%)

As of 04:10 PM Eastern

Compare

STTK vs. CDNA, NKTR, VERA, PHVS, and PGEN

Should you buy Shattuck Labs stock or one of its competitors? Shattuck Labs's main competitors and comparable companies include CareDx (CDNA), Nektar Therapeutics (NKTR), Vera Therapeutics (VERA), Pharvaris (PHVS), and Precigen (PGEN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Shattuck Labs compare to CareDx?

Shattuck Labs (NASDAQ:STTK) and CareDx (NASDAQ:CDNA) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation and dividends.

Shattuck Labs currently has a consensus target price of $12.78, indicating a potential upside of 114.03%. CareDx has a consensus target price of $51.20, indicating a potential downside of 2.74%. Given Shattuck Labs' stronger consensus rating and higher possible upside, research analysts clearly believe Shattuck Labs is more favorable than CareDx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00
CareDx	0 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.63

Shattuck Labs has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market. Comparatively, CareDx has a beta of 2.43, indicating that its share price is 143% more volatile than the broader market.

CareDx has higher revenue and earnings than Shattuck Labs. Shattuck Labs is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$1M	599.17	-$48.81M	-$0.51	N/A
CareDx	$379.80M	7.17	-$21.35M	$2.07	25.43

CareDx has a net margin of 24.23% compared to Shattuck Labs' net margin of 0.00%. CareDx's return on equity of 2.87% beat Shattuck Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-43.57%	-40.90%
CareDx	24.23%	2.87%	2.17%

In the previous week, CareDx had 2 more articles in the media than Shattuck Labs. MarketBeat recorded 5 mentions for CareDx and 3 mentions for Shattuck Labs. Shattuck Labs' average media sentiment score of 1.69 beat CareDx's score of 1.05 indicating that Shattuck Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Shattuck Labs	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
CareDx	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

58.7% of Shattuck Labs shares are owned by institutional investors. 8.8% of Shattuck Labs shares are owned by company insiders. Comparatively, 2.4% of CareDx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

CareDx beats Shattuck Labs on 9 of the 17 factors compared between the two stocks.

How does Shattuck Labs compare to Nektar Therapeutics?

Shattuck Labs (NASDAQ:STTK) and Nektar Therapeutics (NASDAQ:NKTR) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, valuation, profitability, analyst recommendations, dividends, earnings and institutional ownership.

Shattuck Labs has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market. Comparatively, Nektar Therapeutics has a beta of 1.14, indicating that its share price is 14% more volatile than the broader market.

Shattuck Labs has a net margin of 0.00% compared to Nektar Therapeutics' net margin of -287.84%. Nektar Therapeutics' return on equity of -37.87% beat Shattuck Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-43.57%	-40.90%
Nektar Therapeutics	-287.84%	-37.87%	-25.67%

In the previous week, Nektar Therapeutics had 2 more articles in the media than Shattuck Labs. MarketBeat recorded 5 mentions for Nektar Therapeutics and 3 mentions for Shattuck Labs. Shattuck Labs' average media sentiment score of 1.69 beat Nektar Therapeutics' score of 0.84 indicating that Shattuck Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Shattuck Labs	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Nektar Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Shattuck Labs has higher earnings, but lower revenue than Nektar Therapeutics. Shattuck Labs is trading at a lower price-to-earnings ratio than Nektar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$1M	599.17	-$48.81M	-$0.51	N/A
Nektar Therapeutics	$54.59M	41.68	-$164.08M	-$6.70	N/A

58.7% of Shattuck Labs shares are owned by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are owned by institutional investors. 8.8% of Shattuck Labs shares are owned by company insiders. Comparatively, 2.5% of Nektar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Shattuck Labs currently has a consensus price target of $12.78, suggesting a potential upside of 114.03%. Nektar Therapeutics has a consensus price target of $141.50, suggesting a potential upside of 112.33%. Given Shattuck Labs' stronger consensus rating and higher possible upside, equities analysts clearly believe Shattuck Labs is more favorable than Nektar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00
Nektar Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

Summary

Shattuck Labs beats Nektar Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Shattuck Labs compare to Vera Therapeutics?

Vera Therapeutics (NASDAQ:VERA) and Shattuck Labs (NASDAQ:STTK) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership and earnings.

Shattuck Labs' return on equity of -43.57% beat Vera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vera Therapeutics	N/A	-84.13%	-66.79%
Shattuck Labs	N/A	-43.57%	-40.90%

In the previous week, Vera Therapeutics had 15 more articles in the media than Shattuck Labs. MarketBeat recorded 18 mentions for Vera Therapeutics and 3 mentions for Shattuck Labs. Shattuck Labs' average media sentiment score of 1.69 beat Vera Therapeutics' score of 1.23 indicating that Shattuck Labs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vera Therapeutics	9 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Shattuck Labs	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Vera Therapeutics has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market. Comparatively, Shattuck Labs has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market.

Vera Therapeutics presently has a consensus target price of $80.15, suggesting a potential upside of 138.06%. Shattuck Labs has a consensus target price of $12.78, suggesting a potential upside of 114.03%. Given Vera Therapeutics' higher probable upside, equities research analysts plainly believe Vera Therapeutics is more favorable than Shattuck Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00

Shattuck Labs has higher revenue and earnings than Vera Therapeutics. Shattuck Labs is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.86	N/A
Shattuck Labs	$1M	599.17	-$48.81M	-$0.51	N/A

99.2% of Vera Therapeutics shares are owned by institutional investors. Comparatively, 58.7% of Shattuck Labs shares are owned by institutional investors. 15.9% of Vera Therapeutics shares are owned by insiders. Comparatively, 8.8% of Shattuck Labs shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Shattuck Labs beats Vera Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Shattuck Labs compare to Pharvaris?

Pharvaris (NASDAQ:PHVS) and Shattuck Labs (NASDAQ:STTK) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.

Shattuck Labs has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than Shattuck Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharvaris	N/A	N/A	-$198.79M	-$3.05	N/A
Shattuck Labs	$1M	599.17	-$48.81M	-$0.51	N/A

Pharvaris currently has a consensus target price of $59.87, suggesting a potential upside of 57.30%. Shattuck Labs has a consensus target price of $12.78, suggesting a potential upside of 114.03%. Given Shattuck Labs' stronger consensus rating and higher possible upside, analysts clearly believe Shattuck Labs is more favorable than Pharvaris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharvaris	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Pharvaris had 34 more articles in the media than Shattuck Labs. MarketBeat recorded 37 mentions for Pharvaris and 3 mentions for Shattuck Labs. Shattuck Labs' average media sentiment score of 1.69 beat Pharvaris' score of 0.52 indicating that Shattuck Labs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharvaris	13 Very Positive mention(s)	5 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Shattuck Labs	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Shattuck Labs' return on equity of -43.57% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharvaris	N/A	-61.40%	-56.00%
Shattuck Labs	N/A	-43.57%	-40.90%

58.7% of Shattuck Labs shares are owned by institutional investors. 8.8% of Shattuck Labs shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Pharvaris has a beta of -2.33, indicating that its stock price is 333% less volatile than the broader market. Comparatively, Shattuck Labs has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market.

Summary

Shattuck Labs beats Pharvaris on 13 of the 15 factors compared between the two stocks.

How does Shattuck Labs compare to Precigen?

Shattuck Labs (NASDAQ:STTK) and Precigen (NASDAQ:PGEN) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations.

In the previous week, Shattuck Labs had 1 more articles in the media than Precigen. MarketBeat recorded 3 mentions for Shattuck Labs and 2 mentions for Precigen. Shattuck Labs' average media sentiment score of 1.69 beat Precigen's score of 1.40 indicating that Shattuck Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Shattuck Labs	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Precigen	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Shattuck Labs has a net margin of 0.00% compared to Precigen's net margin of -183.98%. Precigen's return on equity of 423.75% beat Shattuck Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-43.57%	-40.90%
Precigen	-183.98%	423.75%	84.39%

Shattuck Labs presently has a consensus price target of $12.78, indicating a potential upside of 114.03%. Precigen has a consensus price target of $14.50, indicating a potential upside of 107.14%. Given Shattuck Labs' stronger consensus rating and higher probable upside, equities research analysts plainly believe Shattuck Labs is more favorable than Precigen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00
Precigen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Shattuck Labs has higher earnings, but lower revenue than Precigen. Shattuck Labs is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$1M	599.17	-$48.81M	-$0.51	N/A
Precigen	$85.72M	29.11	-$250.64M	-$1.04	N/A

Shattuck Labs has a beta of 1.09, meaning that its stock price is 9% more volatile than the broader market. Comparatively, Precigen has a beta of 1.02, meaning that its stock price is 2% more volatile than the broader market.

58.7% of Shattuck Labs shares are owned by institutional investors. Comparatively, 33.5% of Precigen shares are owned by institutional investors. 8.8% of Shattuck Labs shares are owned by company insiders. Comparatively, 41.4% of Precigen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Shattuck Labs beats Precigen on 12 of the 17 factors compared between the two stocks.

Get Shattuck Labs News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

STTK vs. The Competition

Export

Metric	Shattuck Labs	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$599.17M	$3.82B	$7.16B	$14.34B
Dividend Yield	N/A	3.66%	2.57%	11.71%
P/E Ratio	-11.71	14.21	273.41	25.32
Price / Sales	599.17	1,541.42	674.51	98.42
Price / Cash	N/A	43.64	28.42	34.96
Price / Book	4.59	15.19	10.38	6.20
Net Income	-$48.81M	-$22.78M	$3.49B	$358.18M
7 Day Performance	-8.15%	-2.49%	-2.17%	-1.58%
1 Month Performance	-19.54%	0.34%	-0.37%	-3.60%
1 Year Performance	233.52%	39.39%	19.18%	5.95%

Shattuck Labs Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
STTK Shattuck Labs	3.6416 of 5 stars	$5.97 -3.7%	$12.78 +114.0%	+222.9%	$599.17M	$1M	N/A	40	Positive News
CDNA CareDx	2.7424 of 5 stars	$50.31 -1.1%	$51.20 +1.8%	+287.1%	$2.60B	$458.09M	24.30	740	Positive News
NKTR Nektar Therapeutics	2.7217 of 5 stars	$75.44 +1.7%	$141.50 +87.6%	+40.7%	$2.58B	$55.23M	N/A	220
VERA Vera Therapeutics	3.081 of 5 stars	$35.28 -1.7%	$80.15 +127.2%	+43.2%	$2.54B	N/A	N/A	40	Trending News Analyst Forecast Options Volume Gap Up
PHVS Pharvaris	3.5856 of 5 stars	$37.84 +7.3%	$53.00 +40.1%	+67.5%	$2.48B	N/A	N/A	30	Trending News Analyst Forecast Insider Trade High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:STTK) was last updated on 9/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Shattuck Labs (STTK) Competitors

STTK vs. CDNA, NKTR, VERA, PHVS, and PGEN

How does Shattuck Labs compare to CareDx?

Summary

How does Shattuck Labs compare to Nektar Therapeutics?

Summary

How does Shattuck Labs compare to Vera Therapeutics?

Summary

How does Shattuck Labs compare to Pharvaris?

Summary

How does Shattuck Labs compare to Precigen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STTK vs. The Competition

Shattuck Labs Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Shattuck Labs (STTK) Competitors

STTK vs. CDNA, NKTR, VERA, PHVS, and PGEN

How does Shattuck Labs compare to CareDx?

Do analysts rate STTK or CDNA?

Which has more volatility & risk, STTK or CDNA?

Which has preferable earnings and valuation, STTK or CDNA?

Is STTK or CDNA more profitable?

Does the media prefer STTK or CDNA?

Do insiders and institutionals believe in STTK or CDNA?

Summary

How does Shattuck Labs compare to Nektar Therapeutics?

Which has more volatility & risk, STTK or NKTR?

Is STTK or NKTR more profitable?

Does the media favor STTK or NKTR?

Which has better valuation & earnings, STTK or NKTR?

Do insiders & institutionals hold more shares of STTK or NKTR?

Do analysts prefer STTK or NKTR?

Summary

How does Shattuck Labs compare to Vera Therapeutics?

Is VERA or STTK more profitable?

Does the media favor VERA or STTK?

Which has more volatility and risk, VERA or STTK?

Do analysts prefer VERA or STTK?

Which has higher earnings and valuation, VERA or STTK?

Do institutionals and insiders hold more shares of VERA or STTK?

Summary

How does Shattuck Labs compare to Pharvaris?

Which has preferable valuation and earnings, PHVS or STTK?

Do analysts prefer PHVS or STTK?

Does the media refer more to PHVS or STTK?

Is PHVS or STTK more profitable?

Do institutionals & insiders hold more shares of PHVS or STTK?

Which has more risk & volatility, PHVS or STTK?

Summary

How does Shattuck Labs compare to Precigen?

Does the media favor STTK or PGEN?

Is STTK or PGEN more profitable?

Do analysts rate STTK or PGEN?

Which has preferable earnings and valuation, STTK or PGEN?

Which has more risk and volatility, STTK or PGEN?

Do insiders and institutionals believe in STTK or PGEN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STTK vs. The Competition

Shattuck Labs Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools